DE602004027367D1 - Chinazolinonderivate und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen mit parp-inhibierender wirkung - Google Patents

Chinazolinonderivate und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen mit parp-inhibierender wirkung

Info

Publication number
DE602004027367D1
DE602004027367D1 DE602004027367T DE602004027367T DE602004027367D1 DE 602004027367 D1 DE602004027367 D1 DE 602004027367D1 DE 602004027367 T DE602004027367 T DE 602004027367T DE 602004027367 T DE602004027367 T DE 602004027367T DE 602004027367 D1 DE602004027367 D1 DE 602004027367D1
Authority
DE
Germany
Prior art keywords
parp
preparation
hydrogen
general formula
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027367T
Other languages
English (en)
Inventor
Tudomanyegyetem Pecsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pecsi Tudomanyegyetem
Original Assignee
Pecsi Tudomanyegyetem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pecsi Tudomanyegyetem filed Critical Pecsi Tudomanyegyetem
Publication of DE602004027367D1 publication Critical patent/DE602004027367D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004027367T 2003-04-30 2004-04-30 Chinazolinonderivate und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen mit parp-inhibierender wirkung Expired - Lifetime DE602004027367D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0301173A HU227948B1 (en) 2003-04-30 2003-04-30 Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
PCT/HU2004/000044 WO2004096779A1 (en) 2003-04-30 2004-04-30 Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect

Publications (1)

Publication Number Publication Date
DE602004027367D1 true DE602004027367D1 (de) 2010-07-08

Family

ID=89981336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027367T Expired - Lifetime DE602004027367D1 (de) 2003-04-30 2004-04-30 Chinazolinonderivate und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen mit parp-inhibierender wirkung

Country Status (9)

Country Link
US (1) US7994182B2 (de)
EP (1) EP1622881B1 (de)
AT (1) ATE469133T1 (de)
DE (1) DE602004027367D1 (de)
ES (1) ES2346438T3 (de)
HU (1) HU227948B1 (de)
PL (1) PL1622881T3 (de)
SI (1) SI1622881T1 (de)
WO (1) WO2004096779A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
PL2611300T3 (pl) * 2010-09-03 2016-10-31 Podstawione skondensowane pochodne dihydropirymidynonów
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN106083741A (zh) * 2016-02-22 2016-11-09 南京中医药大学 2‑硫代喹唑啉二酮衍生物
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073826A (en) * 1960-10-20 1963-01-15 Mead Johnson & Co 3-pyrrolidylmethyl-4-quinazolones
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 4(3h)−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1396488A1 (de) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Kondensierte heterocyclische verbindung und deren medizinische verwendung

Also Published As

Publication number Publication date
ES2346438T3 (es) 2010-10-15
WO2004096779A1 (en) 2004-11-11
EP1622881A1 (de) 2006-02-08
HUP0301173A3 (en) 2008-08-28
HU0301173D0 (en) 2003-07-28
ATE469133T1 (de) 2010-06-15
HU227948B1 (en) 2012-07-30
US7994182B2 (en) 2011-08-09
PL1622881T3 (pl) 2010-10-29
SI1622881T1 (sl) 2010-09-30
US20070042935A1 (en) 2007-02-22
EP1622881B1 (de) 2010-05-26
HUP0301173A2 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20051263L (no) Ny anvendelse av benzotiazolderivater
ATE355064T1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
DE60238042D1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11-beta-hydroxysteroid dehydrogenase
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
SE0202462D0 (sv) Novel use
DE502004006507D1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
NO20022201L (no) Lösninger inneholdende Epinastin
DE602004027367D1 (de) Chinazolinonderivate und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen mit parp-inhibierender wirkung
SE9701304D0 (sv) Compounds
BR0315801A (pt) Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DE60328819D1 (de) Indol-3-carboxamide, deren herstellung und therapeutische verwendung
DE69903053T2 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
WO2003066594A3 (de) 3-alkanoylamino-propionsäure-derivate als inhibitoren des integrins avss6
IT1256320B (it) Derivati eterociclici
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
DE60210981D1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
EA200700208A1 (ru) Новая псевдополиморфная форма деслоратадина, образованная с диоксидом углерода
ATE288910T1 (de) Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
BRPI0417140A (pt) derivados quinolina ácidos e seu uso na prevenção e/ou tratamento de patologias relacionadas com hiperglicemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition